PFIZER INC.

Pfizer's Phase 2 study of ponsegromab met its primary endpoint, showing a 5.6% mean increase in body weight at the highest dose compared to placebo in cancer cachexia patients. Ponsegromab was safe and well-tolerated, with improvements in appetite, cachexia symptoms, physical activity, and muscle mass. Registration-enabling studies are planned for 2025.

Pfizer's Phase 2 study of ponsegromab, targeting GDF-15 in cancer cachexia, showed significant weight gain and improvements in muscle mass, quality of life, and physical function. Positive results pave way for registration-enabling studies in 2025. Additionally, Pfizer's RSV vaccine, ABRYSVO, showed potential to protect high-risk adults from RSV in a Phase 3 trial.

Pfizer's experimental drug ponsegromab, targeting cancer-related cachexia, shows promising results in phase 2 clinical tests, potentially improving weight, muscle mass, and quality of life for patients.

$99 for the first year includes FT newspaper Monday-Saturday, FT Digital Edition, FT Weekend, global news & analysis, expert opinion, special features, and exclusive FT analysis.

Merck's stock has risen 72% in 5 years, driven by Keytruda's success, but faces uncertainty as Keytruda's patent expires in 2028. Merck forecasts 2024 revenue growth of 5-7% and seeks new blockbusters, while competition from biosimilars and alternative treatments poses risks.